Clinical Trials
19 trialsNCT01333046 2026-06-03
TACTAL
Baylor College of Medicine
Phase 1 Active not recruiting
NCT07623850 2026-06-03
JLM019
Jecho Biopharmaceuticals Co., Ltd.
Phase 1 Recruiting
NCT01087294 2026-06-01
Administration of Anti-CD19-chimeric-antigen-receptor-transduced T Cells From the Original Transplant Donor to Patients With Recurrent or Persistent B-cell Malignancies After Allogeneic Stem Cell Transplantation
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT04640779 2026-05-28
Low-Dose Selinexor and Choline Salicylate for Non-Hodgkin or Hodgkin Lymphoma, Histiocytic/Dendritic Cell Neoplasm, or Relapsed or Refractory Multiple Myeloma
Mayo Clinic
Phase 1 Completed
NCT07451054 2026-05-14
CD45BE-HSPC + CART-45 Cells
University of Pennsylvania
Phase 1 Not yet recruiting
NCT05272384 2026-05-13
Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma
National Cancer Institute (NCI)
Phase 1 Recruiting
NCT06254495 2026-05-08
A Safety Study of PF-08046044/SGN-35C in Adults With Advanced Cancers
Seagen Inc.
Phase 1 Terminated
NCT06870487 2026-05-08
A Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced Cancers
Pfizer
Phase 1 Terminated
NCT07444632 2026-05-08
Phase1 Basket Trial Of CAR.70-Engineered IL15-Transduced With TGFBR2 Knock Out Cord Blood-Derived NK Cells For Relapsed/Refractory Lymphoid Malignancies
M.D. Anderson Cancer Center
Phase 1 Not yet recruiting
NCT00641381 2026-05-04
Carmustine, Etoposide, Cyclophosphamide, and Stem Cell Transplant in Treating Patients With HIV-Associated Lymphoma
City of Hope Medical Center
Phase 1 Completed
NCT06150664 2026-04-20
A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
Compass Therapeutics
Phase 1 Recruiting
NCT05605119 2026-04-17
SURYA-1
Aurigene Discovery Technologies Limited
Phase 1 Terminated
NCT06761586 2026-04-17
VIJAY-1
Aurigene Discovery Technologies Limited
Phase 1 Terminated
NCT06176690 2026-04-13
CABAL2
Baylor College of Medicine
Phase 1 Recruiting
NCT06487624 2026-04-13
An Engineered Sirpα Fused to Anti-Pd-L1 And Tgf-β Fusion Protein (HCB301) in Subjects With Selected Advanced Tumors
FBD Biologics Limited
Phase 1 Recruiting
NCT05544968 2026-04-03
Anti-CD30 biAb-AATC in Patients With Relapsed/Refractory CD30 Positive Hematopoietic Malignancies
Medical College of Wisconsin
Phase 1 Recruiting
NCT07020533 2026-03-27
A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant
City of Hope Medical Center
Phase 1 Recruiting
NCT02287311 2026-03-23
MABEL
Baylor College of Medicine
Phase 1 Active not recruiting
NCT03478462 2026-03-18
CLOVER-2
Cellectar Biosciences, Inc.
Phase 1 Active not recruiting